Alpha Tau Medical Ltd Cash Flow Conversion Efficiency
Alpha Tau Medical Ltd cash flow conversion efficiency. Based on the latest financial reports, Alpha Tau Medical Ltd (DRTS) has a cash flow conversion efficiency ratio of 0.000x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.78K) by net assets ($89.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alpha Tau Medical Ltd (2019–2024)
Cash flow conversion efficiency of Alpha Tau Medical Ltd from 2019 to 2024. This chart illustrates how Alpha Tau Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alpha Tau Medical Ltd (DRTS) stock price for real-time trading data and today's change.
Alpha Tau Medical Ltd Cash Flow Conversion Ratio Explained
Alpha Tau Medical Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alpha Tau Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alpha Tau Medical Ltd ranked by their cash flow conversion efficiency. Also see Alpha Tau Medical Ltd (DRTS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
0.012x |
|
GMR Solutions Inc.
NYSE:GMRS
|
0.605x |
|
Shanghai Zhongzhou Special Alloy Materials Co. Ltd.
SHE:300963
|
-0.045x |
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
0.031x |
|
SurModics Inc
NASDAQ:SRDX
|
0.013x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
CJ ENM CO. Ltd
KQ:035760
|
0.103x |
Annual Cash Flow Conversion Efficiency for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Alpha Tau Medical Ltd from 2019 to 2024. Review free cash flow generation of Alpha Tau Medical Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $62.67 Million | $-19.78 Million | -0.316x | -48.50% |
| 2023-12-31 | $84.47 Million | $-17.96 Million | -0.213x | +5.94% |
| 2022-12-31 | $105.66 Million | $-23.88 Million | -0.226x | -166.54% |
| 2021-12-31 | $-34.78 Million | $-11.81 Million | 0.340x | -60.52% |
| 2020-12-31 | $-8.43 Million | $-7.25 Million | 0.860x | -97.60% |
| 2019-12-31 | $-193.00K | $-6.91 Million | 35.803x | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more